Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046182 | 1.00 | TRPA1 (0.40) | TRPA1GAAMAPTALOX15HSD17B10 | |
| SCHEMBL17667601 | 0.87 | GAA (0.39) | TRPA1GAAMAPTALOX15HSD17B10 | |
| SCHEMBL17667600 | 0.87 | GAA (0.39) | TRPA1GAAMAPTALOX15HSD17B10 | |
| SCHEMBL17667590 | 0.80 | GAA (0.39) | GAAMAPTALOX15HSD17B10CMA1 | |
| SCHEMBL17667588 | 0.80 | GAA (0.39) | GAAMAPTALOX15HSD17B10CMA1 | |
| SCHEMBL517634 | 0.80 | ALOX15 (0.52) | GAAMAPTALOX15HSD17B10AHR | |
| SCHEMBL29749158 | 0.80 | ALOX15 (0.52) | GAAMAPTALOX15HSD17B10AHR | |
| SCHEMBL517635 | 0.80 | ALOX15 (0.52) | GAAMAPTALOX15HSD17B10AHR | |
| SCHEMBL4050739 | 0.80 | AHR (0.35) | TRPA1CMA1AHRPNMTASIC3 | |
| SCHEMBL4050744 | 0.80 | AHR (0.35) | TRPA1CMA1AHRPNMTASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720613-A4 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1720613-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | Bristol-Myers Squibb Company (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
| WO-2005084296-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | TRPA1 4866/4885GAA 811/4885MAPT 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.